Condition: Myelodysplastic Syndromes · Sponsor: GlaxoSmithKline
The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Goodyear, Arizona, United States | Recruiting |
| GSK Investigational Site | Duarte, California, United States | Recruiting |
| GSK Investigational Site | Irvine, California, United States | Recruiting |
| GSK Investigational Site | New Haven, Connecticut, United States | Recruiting |
| GSK Investigational Site | Canton, Ohio, United States | Recruiting |
| GSK Investigational Site | Houston, Texas, United States | Recruiting |
| GSK Investigational Site | Calgary, Alberta, Canada | Recruiting |
| GSK Investigational Site | Toronto, Ontario, Canada | Recruiting |
| GSK Investigational Site | Le Mans, France | Recruiting |
| GSK Investigational Site | Nice, France | Recruiting |
| GSK Investigational Site | Paris, France | Recruiting |
| GSK Investigational Site | Poitiers, France | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06847867